Johnson & Johnson (JNJ) Stock Analysis
$JNJ · Healthcare · Drug Manufacturers - General · NYSE
Johnson & Johnson (JNJ), a Drug Manufacturers - General company, is listed on NYSE, has a market capitalization of about $615.87B and trades at 38.7x trailing earnings.
Price
$255.56
Market cap
$615.87B
P/E ratio
38.7x
Dividend yield
2.07%
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
How StockWorthy values JNJ
StockWorthy forecasts Johnson & Johnson's revenue, operating profitability, reinvestment (capital expenditure, depreciation and working capital) and unlevered free cash flow, then discounts those cash flows using a normalized cost of capital built from JNJ's size, profitability and balance-sheet risk. Terminal growth is adjusted to reflect the company's mature growth profile rather than a fixed number. The model presents bear, base and bull scenarios, and every key assumption stays transparent and adjustable in the full StockWorthy analysis. Results are educational and not investment advice.
Related stocks
See JNJ's Fair Value
Create a free account to view Johnson & Johnson's base-case fair value, the bear–bull modeled range, and every assumption behind them. Free accounts include 5 stock valuations per month — plus Advanced DCF models, financial charts, dividends, and peer analysis.